Characterization and drug resistance patterns of ewing's sarcoma family tumor cell lines

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  May, William A ^a,b   Grigoryan, Rita S ^a,b   Keshelava, Nino ^a,b   Cabral, Daniel J ^d   Christensen, Laura L ^a,b   Jenabi, Jasmine ^a   Ji, Lingyun ^a   Triche, Timothy J ^a,b   Lawlor, Elizabeth R ^c   Reynolds, C Patrick ^d  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FIRTECAN; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MENSA; PROTEIN P14; PROTEIN P16; PROTEIN P53; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DRUG MEGADOSE; DRUG SENSITIVITY; EWING SARCOMA; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MYELOABLATIVE CONDITIONING; PRESCHOOL CHILD; PROTEIN FUNCTION; SCHOOL CHILD; SHORT TANDEM REPEAT; TUMOR CELL LINE; YOUNG ADULT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; SARCOMA, EWING; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891590494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080060     Document Type: Article

References (63)

1. Balamuth NJ, Womer RB (2010) Ewing's sarcoma. Lancet Oncol 11: 184-192.
2. Burchill SA (2003) Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol 56: 96-102.
3. Rodriguez-Galindo C, Spunt SL, Pappo AS (2003) Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 40: 276-287.
4. Arvand A, Denny CT (2001) Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20: 5747-5754.
5. Janknecht R (2005) EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363: 1-14.
6. Toomey EC, Schiffman JD, Lessnick SL (2010) Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 29: 4504-4516.
7. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, et al. (2005) An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754.
8. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, et al. (2000) Prognostic impact of P53 status in Ewing sarcoma. Cancer 89: 783-792.
9. Amir G, Issakov J, Meller I, Sucher E, Peyser A, et al. (2002) Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. Hum Pathol 33: 170-174.
10. Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, et al. (1999) Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 79: 1185-1189.
11. Honoki K, Stojanovski E, McEvoy M, Fujii H, Tsujiuchi T, et al. (2007) Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. Cancer 110: 1351-1360.
12. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, et al. (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23: 548-558.
13. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, et al. (2000) Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89: 793-799.
14. Meier VS, Kuhne T, Jundt G, Gudat F (1998) Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 7: 29-35.
15. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, et al. (2008) The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27: 3282-3291.
16. Labuhn M, Jones G, Speel EJ, Maier D, Zweifel C, et al. (2001) Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene 20: 1103-1109.
17. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, et al. (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417-1423.
18. Biedler JL, Helson L, Spengler BA (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33: 2643-2652.
19. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, Martinez-Delgado B, Urioste M, et al. (2003) Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 141: 138-142.
20. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Kao-Shan S, et al. (1986) Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genetics and Cytogenetics 21: 185-208.
21. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, et al. (1984) Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 311: 584-585.
22. Batra S, Reynolds CP, Maurer BJ (2004) Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 64: 5415-5424.
23. Martini J, Schmied K, Palmisano R, Toensing K, Anselmetti D, et al. (2007) Multifocal two-photon laser scanning microscopy combined with photoactivatable GFP for in vivo monitoring of intracellular protein dynamics in real time. J Struct Biol 158: 401-409.
24. Frgala T, Kalous O, Proffitt RT, Reynolds CP (2007) A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 6: 886-897.
25. Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP (2005) DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 110: 139-153.
26. Projic P, Skaro V, Samija I, Pojskic N, Durmic-Pasic A, et al. (2007) Allele frequencies for 15 short tandem repeat loci in representative sample of Croatian population. Croat Med J 48: 473-477.
27. Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7: 233-245.
28. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, et al. (1996) Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14: 1245-1251.
29. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, et al. (1998) EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16: 1248-1255.
30. Aryee DN, Sommergruber W, Muehlbacher K, Dockhorn-Dworniczak B, Zoubek A, et al. (2000) Variability in gene expression patterns of Ewing tumor cell lines differing in EWS-FLI1 fusion type. Lab Invest 80: 1833-1844.
31. de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindan FJ, et al. (2000) Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 156: 849-855.
32. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, et al. (1999) Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 59: 1428-1432.
33. van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 28: 1989-1994.
34. Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, et al. (1999) EWSFLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 17: 1809-1814.
35. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, et al. (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 98: 8012-8017.
36. Melcher R, Maisch S, Koehler S, Bauer M, Steinlein C, et al. (2005) SKY and genetic fingerprinting reveal a cross-contamination of the putative normal colon epithelial cell line NCOL-1. Cancer Genet Cytogenet 158: 84-87.
37. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, et al. (2000) Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120: 91-98.
38. Kovar H, Jug G, Aryee DN, Zoubek A, Ambros P, et al. (1997) Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15: 2225-2232.
39. Folpe AL, Hill CE, Parham DM, O'Shea PA, Weiss SW (2000) Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 24: 1657-1662.
40. Keshelava N, Groshen S, Reynolds CP (2000) Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer ChemotherPharmacol 45: 1-8.
41. Keshelava N, Seeger RC, Groshen S, Reynolds CP (1998) Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58: 5396-5405.
42. Sethi VS, Jackson DV, Jr., White DR, Richards F, Stuart JJ, et al. (1981) Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41: 3551-3555.
43. Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, et al. (1987) Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res 47: 2723-2726.
44. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47: 1952-1956.
45. Boos J, Krumpelmann S, Schulze-Westhoff P, Euting T, Berthold F, et al. (1995) Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 13: 2954-2960.
46. Ma MK, Zamboni WC, Radomski KM, Furman WL, Santana VM, et al. (2000) Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 6: 813-819.
47. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, et al. (1996) Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 18: 352-361.
48. Sabbagh R, Leclerc J, Sunderland M, Theoret Y (1993) Chronopharmacokinetic of a 48-hr continuous infusion of doxorubicin to children with acute lymphoblastic leukemia. Proc Am Assoc Cancer Res 34: 198.
49. D'Incalci M, Farina P, Sessa C, Mangioni C, Conter V, et al. (1982) Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 7: 141-145.
50. Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, et al. (1996) Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 14: 1504-1511.
51. Guilhaumou R, Simon N, Quaranta S, Verschuur A, Lacarelle B, et al. (2011) Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother Pharmacol 68: 1191-1198.
52. McCune JS, Salinger DH, Vicini P, Oglesby C, Blough DK, et al. (2009) Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol 49: 88-102.
53. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, et al. (1994) A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 73: 1297-1301.
54. Whelan JS, McTiernan A, Kakouri E, Kilby A (2004) Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 43: 237-242.
55. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, et al. (2006) Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 47: 22-29.
56. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M (2007) Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr Blood Cancer 49: 196-198.
57. Al-Faris N, Al Harbi T, Goia C, Pappo A, Doyle J, et al. (2007) Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer 49: 190-195.
58. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, et al. (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11: 1451-1462.
59. Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, et al. (2006) Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol 24: 3997-4002.
60. Snyder KM, Mackall CL (2007) Therapy for metastatic ESFT: is it time to ask new questions? Pediatr Blood Cancer 49: 115-116.
61. Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, et al. (2007) Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 109: 46-51.
62. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, et al. (2007) The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49: 928-940.
63. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, et al. (2011) National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56: 239-249.